Down 45%, Should You Buy the Dip on Intel?

The stock market faces significant uncertainty following President Trump's tariff announcements and trade war escalation, leading the S&P 500 into a correction. Amid this volatility, long-term investors see opportunities in undervalued stocks like Target and Micron, both poised for potential growth. Target’s shares have dropped 65% due to weak consumer spending and internal issues, while Micron benefits from rising AI demand, suggesting both could double in value over the next two years if they navigate...

When changing jobs, deciding what to do with your 401(k) can be complex, with options to leave it, roll it into a new employer's plan, or transfer it to an IRA. Rolling over to an IRA offers advantages like a wider range of investment options, greater control over assets, and potentially lower fees, but it may also result in less creditor protection and the loss of tax benefits like Net Unrealized Appreciation for employer stock....

In a recent podcast interview, Charles Hoskinson, co-founder of Ethereum and Cardano, predicted Bitcoin could reach $250,000 by the end of 2025, a 194% increase from its current price of $85,000, citing growing global adoption with 659 million users and significant corporate investment, led by MicroStrategy. He also pointed to upcoming crypto legislation expected to create a clearer regulatory framework, potentially attracting major tech companies to crypto. Hoskinson believes a speculative rally could occur by...

Newsmax (NMAX -8.46%) saw its stock rise 11.6% in a shortened trading week, recovering from a significant 49% drop the previous week linked to meme-stock volatility and a legal ruling regarding defamatory statements about Dominion Voting Systems. Despite the S&P 500's 1.5% decline, Newsmax's stock surged due to rebound trading, and the company reported a 26% annual revenue increase last year, with Nielsen data showing substantial viewership growth. However, uncertainty remains about whether this viewership...

President Donald Trump's tariff policies have caused uncertainty across various industries, including pharmaceuticals, even if they haven't directly impacted them yet. Eli Lilly (LLY), a leading pharma stock, could face challenges such as rising raw material costs and potential retaliatory tariffs, which may compress profit margins in the near term. Despite these concerns, Lilly's long-term outlook remains positive due to growth in blockbuster drugs like Mounjaro and Zepbound, along with emerging opportunities in the Alzheimer's...

Twilio (TWLO) experienced a significant decline of 40% from its 52-week high after a strong performance in late 2024 and a mixed quarterly report in February 2025. Despite this downturn, Twilio's focus on AI tools and a growing customer base provide potential for future growth, with expectations of better-than-anticipated results in its upcoming quarterly release on May 1. The company projects its addressable market to reach $119 billion by 2028, supported by an anticipated increase...